Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer targeting the androgen receptor splicing variant 7 (ARv7)

Despite the success of androgen-deprivation therapy (ADT) with the newly developed anti-androgen enzalutamide (Enz, also known as MDV3100) to suppress castration resistant prostate cancer (CRPC) in extending patient survival by an extra 4.8 months, eventually patients die with the development of Enz resistance that may involve the induction of the androgen receptor (AR) splicing variant ARv7. Here we identify an unrecognized role of Natural Killer (NK) cells in the prostate tumor microenvironment that can be better recruited to the CRPC cells to suppress ARv7 expression resulting in suppressing the Enz resistant CRPC cell growth and invasion.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2nFrEE7
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer targeting the androgen receptor splicing variant 7 (ARv7)

Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer

Androgen deprivation therapy (ADT) for patients with metastatic or locally advanced prostate cancer reduces bone mineral density by stimulating receptor activator of nuclear factor kappa-B (RANK) signaling in osteoclasts. The involvement of the RANK/RANKL signaling in ADT-induced acceleration of bone metastasis in castration-insensitive prostate cancer was examined in a murine model using osteoprotegerin (OPG). Male Balb/c nude mice were divided into three groups: the non-castration, castration, and castration + OPG groups.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2okITxv
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer

Free skin cancer screenings to be offered at Shell Houston Open – KPRC Houston

images?q=tbn:ANd9GcTT4-qvSVT6p8x9upb22ZWspeiAfBzN0ORmSC0MpcLNh_TqjoAMqOit3SOLSldwUUw-jqWt3dkq
KPRC Houston
Free skin cancer screenings to be offered at Shell Houston Open
KPRC Houston
He was diagnosed with stage 4 salivary gland cancer. He knew doctors from MD Anderson through their work with the PGA Tour and he contacted them after his diagnosis to get in as a patient right away.

and more »

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oqZH2A
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Free skin cancer screenings to be offered at Shell Houston Open – KPRC Houston

Articles Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

Avelumab showed an acceptable safety profile and antitumour activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for further studies of avelumab in this disease setting.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2okPeJ9
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Articles Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

Articles Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Avelumab has an acceptable toxicity profile up to 20 mg/kg and the maximum tolerated dose was not reached. Based on pharmacokinetics, target occupancy, and immunological analysis, we chose 10 mg/kg every 2 weeks as the dose for further development and phase 3 trials are ongoing.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oIl7aQ
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Articles Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Comment Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types

During the past 5 years, immune checkpoint inhibitors have revolutionised the management and treatment of cancer, because they have been associated with striking improvements in clinical outcomes in patients with some tumour types. For example, the use of checkpoint inhibitors has changed the natural history of melanoma with a pronounced increase in patients’ survival.1,2 These agents have also been tested in many other tumour types, such as renal cancer, urothelial cancer, and squamous cell cancer of the head and neck, with promising results and have subsequently gained approval from the regulatory authorities.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2okyLou
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Comment Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types

Orange Regional offers free cancer screenings – The Chronicle

Orange Regional offers free cancer screenings
The Chronicle
MIDDLETOWN — Orange Regional Medical Center will offer the community free oral, head and neck cancer screenings in conjunction with Oral, Head and Neck Cancer Awareness week, April 2-9. Appointments are available on April 3, April 4 and April 7 at …

and more »

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oqEHZQ
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Orange Regional offers free cancer screenings – The Chronicle